Suven ties up with US-based pharma co
Suven Life Sciences Ltd has signed an agreement with US-based pharmaceutical firm Eli Lilly and Company to carryout pre-clinical research for central nervous system disorder (CNS).
By PTI |
MUMBAI: Suven Life Sciences Ltd has signed an agreement with US-based pharmaceutical firm Eli Lilly and Company to carryout pre-clinical research for central nervous system disorder (CNS).
Suven informed the Bombay Stock Exchange today that it has tied up with Eli Lilly to collaborate on pre-clinical research of molecules in the therapeutic area of CNS.
The company's Vice Chairman and CEO Venkat Jasti said this was Suven's first true research collaboration with a global pharmaceutical company and would help it realize the next step of its strategic vision.
"This effort is a collaboration between Suven and Lilly, with scientists from both parties working together in a team, with the goal of identifying potent, oral compounds that selectively modulate the specified G-Protein Coupled Receptor for the target CNS disease," the company's Vice President, Drug Discovery, Ramakrishna Nirogi said.
The company said it would receive payments from Lilly and potentially downstream payments if the identified candidates are selected by Lilly for further pre-clinical research and development.
Suven informed the Bombay Stock Exchange today that it has tied up with Eli Lilly to collaborate on pre-clinical research of molecules in the therapeutic area of CNS.
The company's Vice Chairman and CEO Venkat Jasti said this was Suven's first true research collaboration with a global pharmaceutical company and would help it realize the next step of its strategic vision.
"This effort is a collaboration between Suven and Lilly, with scientists from both parties working together in a team, with the goal of identifying potent, oral compounds that selectively modulate the specified G-Protein Coupled Receptor for the target CNS disease," the company's Vice President, Drug Discovery, Ramakrishna Nirogi said.
The company said it would receive payments from Lilly and potentially downstream payments if the identified candidates are selected by Lilly for further pre-clinical research and development.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
